Shingles - Pipeline Insight, 2024

Shingles - Pipeline Insight, 2024

DelveInsight’s, “Shingles - Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Shingles pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Shingles: Understanding

Shingles: Overview

Shingles, also known as herpes zoster, is a viral disease caused by the reactivation of the varicella-zoster virus, which remains dormant in the sensory ganglia after an initial chickenpox infection. Typically affecting adults and the elderly, shingles arises when the immune system can no longer keep the virus in check. The incidence of shingles is strongly correlated with immune status, with those maintaining robust immunity rarely developing the condition. Shingles is not merely a benign infection; it can present in various forms and often leads to complications such as postherpetic neuralgia, a persistent and severe pain that continues even after the rash has resolved. Understanding and managing shingles is crucial, especially for those with weakened immune systems, to mitigate its impact and complications.

Shingles, or herpes zoster, typically begins with a prodromal phase characterized by pain, itching, or tingling in a localized area, often accompanied by fever, headache, and malaise. This is followed by the appearance of a painful, blistering rash that usually develops on one side of the body or face, following the path of a sensory nerve. The rash starts as red patches that evolve into fluid-filled blisters, which eventually crust over and heal within two to four weeks. In addition to the acute pain of the rash, many individuals experience severe nerve pain known as postherpetic neuralgia, which can persist long after the visible symptoms have disappeared. Herpes zoster, or shingles, is diagnosed through clinical examination of its characteristic burning pain, rash morphology, and distribution. Diagnostic tests include the Tzanck smear, which identifies multinucleated giant cells but is less sensitive than direct fluorescent antibody (DFA) or polymerase chain reaction (PCR) tests. Varicella-zoster virus-specific IgM antibodies are detected in active infections. DFA and PCR tests, particularly real-time PCR, are preferred for their high sensitivity and rapid results. Differential diagnosis involves distinguishing shingles from other conditions like herpes simplex, contact dermatitis, and dental infections.

The treatment of herpes zoster involves a multifaceted approach aimed at hastening lesion resolution, reducing acute pain, and preventing complications like post-herpetic neuralgia. Antiviral medications such as acyclovir, valacyclovir, and famciclovir are administered to combat the virus and are most effective when started early. Topical antibiotic creams like mupirocin or soframycin are used to prevent secondary bacterial infections. Pain management includes analgesics and, in severe cases, opioid medications, along with topical lidocaine and nerve blocks for additional relief. For managing post-herpetic neuralgia, particularly in elderly patients, topical treatments such as capsaicin and Emla cream are recommended once the lesions have crusted. This comprehensive treatment strategy helps mitigate the immediate and long-term effects of herpes zoster.

""Shingles- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Shingles pipeline landscape is provided which includes the disease overview and Shingles treatment guidelines. The assessment part of the report embraces, in depth Shingles commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Shingles collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Shingles R&D. The therapies under development are focused on novel approaches to treat/improve Shingles.

Shingles Emerging Drugs Chapters

This segment of the Shingles report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Shingles Emerging Drugs

Amezosvatein: Curevo Vaccine

Amezosvatein (CRV-101) is an investigational non-mRNA adjuvanted sub-unit vaccine for the prevention of shingles (herpes zoster in adults and chickenpox (varicella) in children. As a sub-unit vaccine, amezosvatein does not contain virus components and cannot cause infection. Amezosvatein targets glycoprotein E (gE) on the varicella virus, a target proven by others to be safe and effective for the prevention of shingles. The adjuvant component of amezosvatein was specifically engineered with the intent of producing an optimal immune response while improving tolerability. Currently, the drug is in Phase II stage of its clinical trial for the treatment of shingles.

REC610: Jiangsu Recbio Technology

REC610, a novel adjuvanted recombinant shingles vaccine developed by Jiangsu Recbio Technology, received a clinical trial approval notice from the National Medical Products Administration (NMPA) in October 2023. The vaccine demonstrated a positive safety profile in a phase I trial in the Philippines, where it was compared to GSK’s Shingrix. REC610 showed a favorable safety and tolerability profile in healthy participants aged 40 and above after two doses of vaccination, with no serious adverse events reported. The vaccine induced strong gE-specific humoral and cellular immune responses, which peaked at 30 days after the second vaccination. Currently, the drug is in Phase I stage of its clinical trial for the treatment of shingles.

Further product details are provided in the report……..

Shingles: Therapeutic Assessment

This segment of the report provides insights about the different Shingles drugs segregated based on following parameters that define the scope of the report, such as:

MajorPlayers in Shingles

There are approx. 18+ key companies which are developing the therapies for Shingles. The companies which have their Shingles drug candidates in the most advanced stage, i.e. Phase II include, Curevo Vaccine.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Shingles pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Parenteral

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins

Small molecule

Monoclonal antibody

Peptide

Polymer

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Shingles: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Shingles therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Shingles drugs.

Shingles Report Insights

Shingles Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Shingles Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Shingles drugs?

How many Shingles drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Shingles?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Shingles therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Shingles and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Zhuhai Trinomab Pharmaceutical

Nobelpharma

Dynavax Technologies Corporation

Jiangsu Rec-Biotechnology

Moderna

Curevo

Amytrx Therapeutics

Key Products

TNM005

NPC-06

Z-1018

REC610

mRNA-1468

CRV 101

AMTX 100